Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $596
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated VRTX | 0.00 |
Morgan Stanley analyst Terence Flynn maintains Vertex Pharmaceuticals (NASDAQ:
VRTX) with a Overweight and raises the price target from $570 to $596.
